Article Sidebar
Published:
Jun 12, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Pegylated niosomal nanoparticles loaded with vincristine: Characterization and in vitro evaluation
Abstract
Purpose: To investigate the effect of pegylated niosomal vincristine (VCR) on enhanced performance, drug resistance and prolonged blood circulation time.
Methods: Pegylated niosomal VCR was synthesized by reverse phase evaporation. The mean diameter, size distribution, and zeta potential of pegylated niosomal VCR were evaluated using a Zetasizer. The half-maximal concentration (IC50) values of pegylated niosomal VCR and standard VCR were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The impact of pegylated niosomal VCR on apoptosis and cell cycle of BCL1 lymphoma cancer cells were investigated.
Results: The mean diameter, size distribution and zeta potential of pegylated niosomal VCR were 220 nm, 0.4, and –18.8 mV, respectively. Cell proliferation was evaluated using the MTT assay. The IC50 values of pegylated niosomal VCR and standard VCR were 1.6 and 3.5 μg/mL, respectively, after a 24-h incubation. The cytotoxicity of pegylated niosomal VCR was twice that of standard VCR. Furthermore, flow cytometric analysis of the cell cycle showed that pegylated niosomal VCR induced greater mitotic arrest than did standard VCR.
Conclusions: The findings demonstrate the effective antitumor activity of pegylated niosomal VCR compared with standard VCR.
Keywords: Niosome, Anti-tumour, Polyethylene glycol, Vincristine, Encapsulation, Lymphoma
